TW201437229A - 抗活化蛋白ｃ之人化單株抗體及其用途 - Google Patents

抗活化蛋白ｃ之人化單株抗體及其用途 Download PDF

Info

Publication number
TW201437229A
TW201437229A TW102143763A TW102143763A TW201437229A TW 201437229 A TW201437229 A TW 201437229A TW 102143763 A TW102143763 A TW 102143763A TW 102143763 A TW102143763 A TW 102143763A TW 201437229 A TW201437229 A TW 201437229A
Authority
TW
Taiwan
Prior art keywords
antibody
seq
cell
apc
residue
Prior art date
Application number
TW102143763A
Other languages
English (en)
Chinese (zh)
Inventor
Xiao-Yan Zhao
Zhuo-Zhi Wang
Ji-Yun Kim
Ying Zhu
Jan Tebbe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of TW201437229A publication Critical patent/TW201437229A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW102143763A 2012-11-29 2013-11-29 抗活化蛋白ｃ之人化單株抗體及其用途 TW201437229A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261731368P 2012-11-29 2012-11-29

Publications (1)

Publication Number Publication Date
TW201437229A true TW201437229A (zh) 2014-10-01

Family

ID=50828440

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102143763A TW201437229A (zh) 2012-11-29 2013-11-29 抗活化蛋白ｃ之人化單株抗體及其用途

Country Status (17)

Country Link
US (2) US9657111B2 (enExample)
EP (1) EP2925360A4 (enExample)
JP (1) JP2016501875A (enExample)
KR (1) KR20150088853A (enExample)
CN (1) CN104936618A (enExample)
AR (1) AR093672A1 (enExample)
AU (1) AU2013352260A1 (enExample)
BR (1) BR112015012458A2 (enExample)
CA (1) CA2892748A1 (enExample)
HK (1) HK1215174A1 (enExample)
IL (1) IL238920A0 (enExample)
MX (1) MX2015006738A (enExample)
RU (1) RU2015125343A (enExample)
SG (1) SG11201504035PA (enExample)
TW (1) TW201437229A (enExample)
UY (1) UY35160A (enExample)
WO (1) WO2014085527A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI857319B (zh) * 2021-07-13 2024-10-01 大陸商上海萊士血液製品股份有限公司 針對人活化蛋白c的單株抗體及其製備和應用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
US12319744B2 (en) 2018-09-06 2025-06-03 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
DE69735421T2 (de) 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6989241B2 (en) 2000-10-02 2006-01-24 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US20030203355A1 (en) 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
DK1963368T6 (da) * 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
AU2006330411B2 (en) * 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
US7846443B2 (en) 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009055669A2 (en) * 2007-10-26 2009-04-30 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein c
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI857319B (zh) * 2021-07-13 2024-10-01 大陸商上海萊士血液製品股份有限公司 針對人活化蛋白c的單株抗體及其製備和應用

Also Published As

Publication number Publication date
MX2015006738A (es) 2015-08-05
AU2013352260A1 (en) 2015-06-11
US20150322164A1 (en) 2015-11-12
AR093672A1 (es) 2015-06-17
UY35160A (es) 2014-06-30
SG11201504035PA (en) 2015-06-29
CA2892748A1 (en) 2014-06-05
HK1215174A1 (zh) 2016-08-19
IL238920A0 (en) 2015-07-30
CN104936618A (zh) 2015-09-23
KR20150088853A (ko) 2015-08-03
USRE49099E1 (en) 2022-06-07
EP2925360A1 (en) 2015-10-07
WO2014085527A1 (en) 2014-06-05
BR112015012458A2 (pt) 2018-02-06
EP2925360A4 (en) 2016-07-13
JP2016501875A (ja) 2016-01-21
US9657111B2 (en) 2017-05-23
RU2015125343A (ru) 2017-01-11

Similar Documents

Publication Publication Date Title
CN113271956B (zh) 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
CN114907446B (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN106163556A (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
US9574013B2 (en) Antibodies against factor XII and uses thereof
CN105658240A (zh) 用于缀合可活化抗体的组合物和方法
KR20140104945A (ko) 항-ａｘｌ 항체 및 그의 용도
KR20140104944A (ko) 항-ａｘｌ 항체 및 그의 용도
CN108112254A (zh) 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR20200070324A (ko) 항-cd71 활성화 가능한 항체 약물 접합체 및 이의 사용 방법
TW201437229A (zh) 抗活化蛋白ｃ之人化單株抗體及其用途
TW202342523A (zh) 抗Ｎｅｃｔｉｎ－４抗體和雙特異性抗體
US11077187B2 (en) Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
WO2015179435A1 (en) Optimized humanized monoclonal antibodies against activated protein c and uses thereof
CN114080396B (zh) 抗-angpt2抗体
TW201609809A (zh) 活化蛋白ｃ之最佳化人化單株抗體及其用途
WO2023284012A1 (zh) 针对人活化蛋白c的单克隆抗体及其制备和应用
TW201609808A (zh) 抗活化蛋白ｃ之人類化單株抗體之抗原決定區基因定位及其用途
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
WO2024168061A2 (en) Antibody molecules binding to sars-cov-2
WO2024189203A1 (en) Anti-gpvi antibodies and functional fragments thereof
JP2022501062A (ja) Ｅｐｎ１を標的とする抗体
CN117500837A (zh) 新型抗栓抗体